Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   43207   clinical trials with a EudraCT protocol, of which   7151   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-002537-41
    Sponsor's Protocol Code Number:20170104
    National Competent Authority:Netherlands - Competent Authority
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-10-13
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedNetherlands - Competent Authority
    A.2EudraCT number2021-002537-41
    A.3Full title of the trial
    A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative
    Colitis
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis
    A.4.1Sponsor's protocol code number20170104
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAmgen Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAmgen Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAmgen Nederland
    B.5.2Functional name of contact pointMedical Information the Netherlands
    B.5.3 Address:
    B.5.3.1Street AddressMinervum 7061
    B.5.3.2Town/ cityBreda
    B.5.3.3Post code4800 DH
    B.5.3.4CountryNetherlands
    B.5.4Telephone number+310765732500
    B.5.5Fax number+310765732838
    B.5.6E-mailmedinfonl@amgen.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEfavaleukin Alfa
    D.3.2Product code AMG 592
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEFAVALEUKIN ALFA
    D.3.9.2Current sponsor codeAMG 592
    D.3.9.4EV Substance CodeSUB195522
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Moderate to Severe Active Ulcerative Colitis
    E.1.1.1Medical condition in easily understood language
    Ulcerative Colitis
    E.1.1.2Therapeutic area Body processes [G] - Immune system processes [G12]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10045365
    E.1.2Term Ulcerative colitis
    E.1.2System Organ Class 100000004856
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the effect of efavaleukin alfa on induction of clinical remission
    E.2.2Secondary objectives of the trial
    To evaluate the effect of efavaleukin alfa on induction of clinical response
    - To evaluate the effect of efavaleukin alfa as induction therapy on endoscopic remission
    - To evaluate the effect of efavaleukin alfa as induction therapy on mucosal healing
    - To evaluate the effect of efavaleukin alfa as induction therapy on change in histological score
    - To evaluate the safety and tolerability of efavaleukin alfa
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    101 Subject has provided informed consent prior to initiation of study .
    102 Aged from 18 years to 80 years at screening visit, except in South Korea where from age 19 years to 80 years at screening visit; and in Taiwan where age from 20 years to 80 years at screening visit.
    103 Diagnosis of UC established at least 3 months prior to enrollment by clinical and endoscopic evidence and corroborated by a histopathology report.
    104 Moderately to severely active UC as defined by a modified Mayo score of 5 to 9, with a centrally read rectosigmoidoscopy endoscopic subscore at least 2 and no subscore less than 1 prior to day 1.
    105 Has documentation of
    A surveillance colonoscopy within 12 months of day 1 visit for subjects with pancolitis of at least 8 years duration, or subjects with left-sided colitis of over 12 years duration, or subjects with
    primary sclerosing cholangitis.
    For all other subjects, up-to-date colorectal cancer surveillance
    (performed according to local standard). Subjects who do not have a
    colonoscopy report available in source documentation will have a
    colonoscopy instead of rectosigmoidoscopy performed as the screening endoscopy for the study, at the discretion of the investigator.
    106 Subjects must have demonstrated inadequate response, loss of response, or intolerance to at least 1 conventional therapy, biologic therapy, or targeted small molecule therapy (ie, JAK-inhibitor).
    Conventional therapy failed subjects:
    - Corticosteroids (corticosteroid-refractory colitis, defined as signs
    and/or symptoms of active UC despite oral prednisone (or equivalent)
    at doses of at least 30 mg/day for a minimum of 2 weeks; or
    corticosteroid-dependent colitis, defined as: an inability to reduce
    corticosteroids below the equivalent of prednisone 10 mg/day within
    3 months of starting corticosteroids without a return of signs and/or
    symptoms of active UC; or a relapse within 3 months of completing a
    course of corticosteroids
    - History of intolerance of corticosteroids (including, but not limited to,
    Cushing's syndrome, osteopenia/osteoporosis, hyperglycemia, or
    neuropsychiatric side-effects, including insomnia, associated with
    corticosteroid treatment)
    - Immunomodulators: signs and/or symptoms of persistently active
    disease despite at least 3 months treatment with one of the following
    at locally approved doses: oral azathioprine or 6-mercaptopurine, or oral azathioprine or 6-mercatopurine within a therapeutic range as judged by thioguanine metabolite testing, or a combination of a thiopurine and allopurinol within a therapeutic range as judged by thioguanine metabolite testing
    - History of intolerance to at least 1 immunomodulator (including but not limited to nausea/vomiting, abdominal pain, pancreatitis, liver function test abnormalities, and lymphopenia) and have neither failed nor demonstrated an intolerance to a biological medication (anti-TNF
    antibody, anti-integrin antibody, or IL-12/23 antagonists) that is
    indicated for the treatment of UC
    Biologic or targeted small molecule therapy failed subjects: those who
    demonstrated inadequate response or loss of response or intolerance to biologic therapy for UC (eg, anti-TNF antibodies or IL-12/23 antagonists, anti-integrin antibodies) or targeted small molecules (eg, JAK inhibitors).
    The therapy used to qualify the subject for entry into this category must be approved for the treatment of UC in the country of use, at the time of use. Subjects must fulfil one of the following criteria:
    Inadequate response: signs and symptoms of persistently active
    disease despite induction treatment at the approved induction dosing
    that was indicated in the product label at the time of use
    Loss of response: recurrence of signs and symptoms of active
    disease during approved maintenance dosing following prior clinical benefit (discontinuation despite clinical benefit does not quality as
    having failed or being intolerant to UC biological therapy or JAK
    inhibitor)
    Intolerance: history of intolerance to infliximab, adalimumab,
    golimumab, vedolizumab, ustekinumab, tofacitinib or other approved
    biologicals or JAK inhibitors (including but not limited to
    infusion-related event, demyelination, congestive heart failure, or any
    other drug-related adverse event that led to a reduction in dose or
    discontinuation of the medication)
    107 If receiving any of the following therapies, subjects must have stable dosage for the specified duration:
     5-aminosalicylates (ASAs), stable dosage for at least 2 weeks prior to screening endoscopy
     Oral corticosteroids: prednisone up to 20 mg/day or its equivalent, stable dose for 2 weeks prior to screening endoscopy
     Budesonide: extended release tablets 9 mg/day [budensonide MMX], stable dose for at least 2 weeks prior to screening endoscopy
     Conventional immunomodulators: azathioprine, 6-mercaptopurine,
    methotrexate, stable dosage for at least 8 weeks prior to screening endoscopy
    E.4Principal exclusion criteria
    201 Diagnosis of Crohn’s disease, inflammatory bowel disease-unclassified, microscopic colitis, ischemic colitis, or clinical findings suggestive of Crohn’s disease.
    202 Disease limited to the rectum.
    203 Evidence of toxic megacolon, fulminant colitis, intra-abdominal abscess, or stricture/stenosis within the small bowel or colon.
    204 Previous bowel resection or intestinal or intra-abdominal surgery.
    Have had extensive surgery for UC, or are likely to require surgery for the treatment of UC during the study. Subjects who have had limited surgery for UC may be allowed in the study, if this does not affect the assessment of efficacy. Discussion with the sponsor must occur prior to screening of such subjects.
    Have had any small bowel or colonic surgery within 6 months of day 1.
    Have had any nonintestinal intra-abdominal surgery within 3 months of day 1.
    205 Adenoma and dysplasia exclusion criteria:
    Any current sporadic adenoma without dysplasia that has not been removed. Once completely removed, the subject is eligible for study.
    Dysplasia occurring in flat mucosa, sporadic adenomas containing dysplasia, and dysplasia-associated lesions or masses will be managed as follows:
    Any history or current evidence of high-grade dysplasia.
    Any history or current evidence of dysplasia occurring in flat mucosa.
    This includes histopathology reporting indefinite for dysplasia, low-grade dysplasia, and high-grade dysplasia.
    Any history or current evidence of a nonadenoma-like
    dysplasia-associated lesions or masses, with or without evidence of
    dysplasia.
    Any current sporadic adenoma containing dysplasia or any current
    adenoma-like dysplasia-associated lesions or masses that has not been
    removed. Once completely removed, the patient is eligible for the study.
    206 Stool positive for Clostridium difficile toxin at screening and other enteric pathogens including but not limited to ova, parasites, Campylobacter, salmonella, shigella, E coli 0157:H7, and Yersinia enterocolitica.
    207 History or evidence of suicidal ideation (severity of 4 or 5) or any suicidal behavior based on an assessment with the Columbia Suicide Severity Rating Scale (C-SSRS) at screening
    208 Active infection for which anti-infectives were indicated within 4 weeks prior to screening visit OR presence of serious infection, defined as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to screening visit.
    209 Active tuberculosis or latent tuberculosis with no documented past history of adequate treatment per local standard of care.
    210 Positive test for TB during screening defined as: either a positive or indeterminate QuantiFERON-TB or T-spot test OR positive purified protein derivative. Subjects with a positive PPD and a history of Bacillus Calmette-Guerin vaccination are allowed to enroll with a negative QuantiFERON®-TB or T-Spot test and negative chest X-ray.
    Indeterminate QuantiFERON®-TB or T-spot test can be repeated once,
    based on investigator judgment. Subjects can enroll if second result is
    negative. Subjects with persistent indeterminate or positive test results must proceed as below.
    Subjects with a positive PPD test or a positive or indeterminate QuantiFERON®-TB or T-Spot test are allowed to enroll if they meet ALL the following criteria at screening:
    No symptoms per tuberculosis worksheet provided by Amgen
    documented history of adequate TB treatment or prophylactic treatment for latent TB
    No known exposure to a case of active tuberculosis after most recent
    treatment/prophylaxis
    Chest X-ray with no new radiographic findings suggestive of active TB
    211 Any history of malignancy
    212 Presence of 1 or more significant concurrent medical conditions per the investigator judgement
    213 Positive for hepatitis B surface antigen (HBsAg); or positive for hepatitis B core antibody or hepatitis B surface antibody in the presence of detectable viral DNA in peripheral blood, assessed by polymerase chain reaction. Subjects positive for HBcAb and/or HBsAb without history of prior vaccination and without detectable viral DNA by PCR are allowed to enroll, provided the subject undergoes monitoring of viral DNA by PCR at every
    2 months during the treatment period and up to 6 weeks after the end of treatment for the study. Patients with a history of hepatitis B vaccination without history of hepatitis B infection are allowed to enroll.
    214 Positive for hepatitis C antibody in the presence of detectable viral RNA in peripheral blood, assessed by PCR. Subjects positive for HCAb without detectable viral RNA by PCR are allowed to enroll.
    215 Known history of Human Immunodeficiency Virus (HIV) or positive HIV test at screening.
    216 Inherited immunodeficiency syndrome.
    217 Required systemic corticosteroid use for any indication other than UC.
    218 Have had a bone marrow or solid organ transplantation.
    219 Have had extra-abdominal surgery without full recovery prior to screening.
    E.5 End points
    E.5.1Primary end point(s)
    Clinical remission at week 12
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 12
    E.5.2Secondary end point(s)
    Clinical response at week 12
    Endoscopic remission at week 12
    Symptomatic remission at week 12
    Combined endoscopic remission and histologic remission of the colon tissue at week 12
    Change from baseline in histological score at week 12 as measured by Geboes score
    Treatment-emergent adverse events
    E.5.2.1Timepoint(s) of evaluation of this end point
    Week 12
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA100
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Austria
    Bulgaria
    Canada
    Czechia
    Denmark
    Finland
    Germany
    Hungary
    Italy
    Japan
    Korea, Democratic People's Republic of
    Mexico
    Netherlands
    Poland
    Romania
    Russian Federation
    Sweden
    Switzerland
    Taiwan
    Turkey
    Ukraine
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of long-term treatment (Long-term extension is additional 40 week +6 week follow-up)
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days24
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 214
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 106
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state6
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 158
    F.4.2.2In the whole clinical trial 320
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    6 week follow up
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-10-13
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-12-08
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA